Factor H binds to washed human platelets.

Vaziri-Sani, F; Hellwage, J; Zipfel, P F; Sjöholm, Anders; Iancu, Ruxandra; Karpman, Diana

Published in:
Journal of Thrombosis and Haemostasis

DOI:
10.1111/j.1538-7836.2004.01010.x

2005

Link to publication

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
Factor H binds to washed human platelets

F. VAZIRI-SANI, J. HELLWAGE,* P. F. ZIPFEL,* A. G. SJÖHOLM,† R. IANCU and D. KARPMAN
Department of Pediatrics, Lund University, Lund, Sweden; *Molecular Immunobiology Group and Department of Infection Biology, Hans Knöll Institute for Natural Products Research, Jena, Germany; and †Institute of Laboratory Medicine, Section for Microbiology, Immunology and Glycobiology, Lund University, Lund, Sweden


Summary. Background: Factor H regulates the alternative pathway of complement. The protein has three heparin-binding sites, is synthesized primarily in the liver and copurifies from platelets with thrombospondin-1. Factor H mutations at the C-terminus are associated with atypical hemolytic uremic syndrome, a condition in which platelets are consumed. Objectives The aim of this study was to investigate if factor H interacts with platelets. Methods: Binding of factor H, recombinant C- or N-terminus constructs and a C-terminus mutant to washed (plasma and complement-free) platelets was analyzed by flow cytometry. Binding of factor H and constructs to thrombospondin-1 was measured by surface plasmon resonance. Results: Factor H bound to platelets in a dose-dependent manner. The major binding site was localized to the C-terminus. The interaction was partially blocked by heparin. Inhibition with anti-GPIIb/IIIa, or with fibrinogen, suggested that the platelet GPIIb/IIIa receptor is involved in factor H binding. Factor H binds to thrombospondin-1. Addition of thrombospondin-1 increased factor H binding to platelets. Factor H mutated at the C-terminus also bound to platelets, albeit to a significantly lesser degree. Conclusions: This study reports a novel property of factor H, i.e. binding to platelets, either directly via the GPIIb/IIIa receptor or indirectly via thrombospondin-1, in the absence of complement. Binding to platelets was mostly mediated by the C-terminal region of factor H and factor H mutated at the C-terminus exhibited reduced binding.

Keywords: complement, factor H, hemolytic uremic syndrome, platelets.

Introduction

Factor H (FH) is a glycoprotein known to play a regulatory role in the activation of the alternative pathway of complement. This plasma protein prevents formation of the C3bBb convertase by competing with factor B and destabilizes the formed convertase by displacing factor B from C3b. It also functions as a cofactor for the proteolytic cleavage of C3b by factor I resulting in the formation of iC3b [1]. FH consists of 20 short consensus repeat (SCR) elements [2]. There are three heparin-binding sites located within SCRs 7, 12–14 and 20 as well as three C3b binding sites at SCRs 1–4, 10–15 and 20 [2–4]. FH circulates in human plasma as a 150-kDa protein, at a concentration of about 500 μg mL⁻¹. The FH-like protein-1 (FHL-1) is a 42-kDa protein which consists of SCRs 1–7, and is derived from the FH transcript by means of alternative splicing. FH and FHL-1 are encoded by a single gene on chromosome 1q32 [5] and both proteins have complement regulatory functions [6].

Homozygous mutations of FH have been found in some patients with membranoproliferative glomerulonephritis and atypical hemolytic uremic syndrome (HUS) (reviewed in [2,7]). Heterozygous FH mutations have been identified in a subgroup of patients with atypical HUS [7–12] and a hot-spot was recognized within SCR 20 [9]. HUS is characterized by a triad of microangiopathic hemolytic anemia, thrombocytopenia and renal failure [13]. The typical form has been associated with infections caused by Shiga toxin producing bacteria in which HUS is usually preceded by a diarrheal prodrome, whereas the atypical form has heterogeneous etiologies [13]. Endothelial cell injury is pivotal to the pathogenesis of HUS [14]. Thrombocytopenia ensues due to platelet consumption in microthrombi, presumably secondary to endothelial cell damage and exposure of the subendothelium. The mechanisms by which FH mutations may lead to HUS are poorly understood. It has been postulated that complement activation may propagate endothelial cell injury [15] and that alterations in FH may thus lead to vascular damage [2,16,17]. A direct interaction of FH with platelets has not been previously studied.

FH is mainly synthesized in the liver, but also in monocytes, fibroblasts, mesangial cells and endothelial cells as summarized by Friese et al. [6]. FH has also been localized to the α-granules of platelets from where it is released upon stimulation with thrombin [18] or upon binding of C3 to the platelet surface [19].

Received 24 March 2004, accepted 16 July 2004
Furthermore, FH was found to copurify from platelets with thrombospondin-1 (Tsp-1) [20], a glycoprotein with a well-characterized role in platelet aggregation [21]. Since FH mutations have been associated with HUS, a condition in which platelet activation is a main manifestation, and since FH is released from platelets, we postulated that native FH interacts directly with platelets. The aim of this study was therefore to investigate binding of normal and mutated FH to washed platelets in the absence of complement.

Materials and methods

FH, recombinant constructs and mutant

Wild-type FH was obtained from Calbiochem (La Jolla, CA, USA). Recombinant histidine-tagged deletion constructs SCR 1–7 (FHL-1), SCR 8–11, SCR 8–20, SCR 15–20 were cloned and expressed in the baculovirus system and purified as described [22]. Recombinant fragments SCRs 1–7, 8–11, 8–20, 15–20 and SCR 15–20mut, histidine-tagged and mutated in SCR 20 at positions R1203E, R1206E, R1210S, K1230S and R1231A, with reduced binding to C3b and heparin, have been previously described [4]. The bioactivity of FH fragments, which are to a certain extent glycosylated [23–25], is comparable to the wild-type [17, 23, 26]. For certain experiments FH was labeled with Alexa555 (Molecular Probes, Leiden, the Netherlands) or 125I. Purity of the proteins (> 95%) was confirmed by SDS–PAGE and by silver staining and no contamination of FH with tsp-1 was found when immunoblotting was performed with rabbit anti-tsp-1 antibody (1:100; Calbiochem).

Platelet-rich plasma and washed (platelet-free) platelets

Venous blood was collected from 44 healthy adult volunteers (22 males and 22 females) not using any medications and platelet-rich plasma (PRP) obtained as described [27]. Platelets were washed of plasma components [27] and resuspended in 1% bovine serum albumin (BSA; ICN Biomedicals, Aurora, OH, USA) in Hank’s balanced salt solution (HBSS without phenol red; Invitrogen, Paisley, UK). The CaCl2 concentration was adjusted to 2.5 mM. Platelets were diluted to a final concentration of 1 × 107 mL−1 in 1% BSA–HBSS. In certain experiments platelets were incubated with mouse antihuman FH antibody (20 μg mL−1; Serotec, Oxford, UK) or mouse IgG1 as an isotype control (Dako, Glostrup, Denmark).

In each experiment platelets were identified by positive immunofluorescence using mouse antihuman CD41–phycoerythrin (PE) antibody (Immunotech) by flow cytometry.

Flow cytometry

Binding of FH, recombinant deletion and mutant constructs to platelets was determined by flow cytometry. Washed thrombin-activated platelets were incubated with or without FH (1, 10 or 100 μg mL−1; 10 μg mL−1 = 0.07 μM) for 1 h at 37 °C and gently mixed every 15 min. Cells were washed and incubated with goat antihuman FH antibody (1:10; Calbiochem) or goat serum as a negative control (1:10; Vector Laboratories, Burlington, CA, USA) for 1 h at 37 °C, both diluted in 1% BSA–HBSS. In separate experiments washed platelets were incubated with mouse antihuman FH antibody (20 μg mL−1; Serotec, Oxford, UK) or mouse IgG1 as an isotype control (Dako, Glostrup, Denmark).

Saturability of binding was tested by incubating increasing concentrations of FH (1, 10, 100, 250, 500, 750, 1000 μg mL−1) with thrombin-activated washed platelets, using the mouse antihuman FH antibody.

Secondary antibodies, rabbit antigoat IgG:FITC (1:400; Calbiochem) or goat F(ab)2 antirabbit IgG:FITC (1:20; Dako), in HEPES buffer [27] were applied as appropriate. Platelets were diluted in 500 μL ice-cold phosphate-buffered saline (PBS; 0.140 M NaCl, 0.003 M KCl, 0.01 M phosphate, pH 7.4; Medicago, Uppsala, Sweden) and binding detected by flow cytometry using a FACS Calibur instrument (FACScan; Becton Dickinson Immunochemistry Systems, San Jose, CA, USA). Acquisition and processing of data from 5000 cells per sample was carried out with the CELLQuest software. Percent binding was calculated after subtraction of the background fluorescence as determined by the binding of the control antibody. Similarly, Alexa555-labeled FH at 50 μg mL−1 was incubated with thrombin-activated platelets.

A F(ab)2 fragment was produced from the polyclonal goat antihuman FH antibody by pepsin digestion (Pierce, Rockford, IL, USA). Inhibition experiments were carried out in which FH 100 μg mL−1 was preincubated with this F(ab)2 fragment (150 μg mL−1) at 37 °C for 1 h before addition to platelets. In these experiments binding was detected with the mouse antihuman FH antibody.

Similarly to experiments with FH, platelets were incubated with 1 and 10 μg mL−1 of SCRs 1–7 (10 μg mL−1 = 0.21 μM), 8–11 (10 μg mL−1 = 0.37 μM), 8–20 (10 μg mL−1 = 0.11 μM), 15–20 (10 μg mL−1 = 0.24 μM) and SCR 15–20mut (10 μg mL−1 = 0.24 μM) and binding detected with the goat antihuman FH antibody.

The importance of the heparin-binding sites was analyzed by preincubation of FH 100 μg mL−1 and SCRs 1–7, 8–11, 8–20, 15–20 as well as SCR 15–20mut (10 μg mL−1) with heparin 1000 IU mL−1 (Leo Pharma, Malmö, Sweden) at 37 °C for 1 h before addition to thrombin-activated washed platelets. Likewise, in separate experiments platelets were first preincubated with heparin before FH was added.
The role of the platelet receptor GPIIb/IIIa for FH binding to platelets was studied by preincubation of thrombin-activated washed platelets with Reopro\(^{\text{TM}}\) (abciximab 100–200 \(\mu\)g mL\(^{-1}\); Eli Lilly, Indianapolis, IN, USA) [29], at room temperature for 15 min, after which platelets were incubated with FH 10 \(\mu\)g or 100 \(\mu\)g mL\(^{-1}\), alternatively SCRs 1–7, 8–20, 15–20 as well as SCR 15–20mut 10 \(\mu\)g mL\(^{-1}\). Similarly, monoclonal antiplatelet receptor GP1b (CD42b, 100 \(\mu\)g mL\(^{-1}\); Dako) was used as a control. In certain experiments platelets were preincubated with Reopro\(^{\text{TM}}\) and FH preincubated with heparin before these were combined.

We investigated if FH competitively inhibits binding of fibrinogen to the GPIIb/IIIa receptor. Platelets were not thrombin-activated in these experiments. The method used for detection of fibrinogen binding has been previously described [27,30]. Washed platelets were incubated with or without FH 10 \(\mu\)g mL\(^{-1}\) or 100 \(\mu\)g mL\(^{-1}\) at 37 \(^\circ\)C for 30 min, washed in PBS and fixed. Cells were then washed and fibrinogen 1 mg mL\(^{-1}\) was added for 5 min at room temperature. Platelets were washed and incubated with FITC-conjugated chicken antihuman fibrinogen antibody (Diapensia, Gothenburg, Sweden) at a final concentration of 100 \(\mu\)g mL\(^{-1}\) or FITC-conjugated chicken antihuman insulin antibody as a negative control (100 \(\mu\)g mL\(^{-1}\); Diapensia), both diluted in HEPES buffer, incubated for 30 min on ice and fluorescence detected.

The possibility that FH binds to platelets via tsp-1 was investigated by preincubation of platelets with rabbit antihuman tsp-1 antibody (1 : 400) for 1 h at 37 \(^\circ\)C prior to addition of FH (100 \(\mu\)g mL\(^{-1}\)) and detection of FH binding as described above. In addition, in some experiments Reopro\(^{\text{TM}}\) was added to the platelets for a further 15 min as described above. In other experiments FH (100 \(\mu\)g mL\(^{-1}\)) was combined with tsp-1 (2 \(\mu\)g mL\(^{-1}\); Sigma) and incubated with thrombin-activated washed platelets. Binding was compared with binding in which FH alone was used. The effect of added tsp-1 was evaluated by 1 h preincubation of tsp-1 with rabbit antihuman tsp-1.

The effect of thrombin activation on tsp-1 expression was tested in washed platelets. Platelets were activated with thrombin or not activated, fixed and incubated with a polyclonal rabbit antihuman tsp-1 (1 : 1500) or rabbit serum (1 : 1500) as a negative control for 1 h at 37 \(^\circ\)C. Platelets were washed and incubated with swine antirabbit IgG:FITC (1 : 20; Dako).

The possible presence of C3 on washed platelets was tested. Platelets were incubated with rabbit antihuman C3c (1 : 50; Dako), or rabbit immunoglobulin fraction (Dako) as a negative control, for 1 h at 37 \(^\circ\)C. Platelets were washed and incubated with swine antirabbit IgG:FITC (1 : 10). As a positive control platelets were incubated for 30 min with 1 mg mL\(^{-1}\) purified C3 [31] at 37 \(^\circ\)C.

Equilibrium and kinetics of FH binding to platelets

The \(K_d\) of FH binding to platelets was measured by a modified Scatchard analysis. Washed platelets were incubated with a combination of radiolabeled \(^{125}\)I-FH (10 \(\mu\)g mL\(^{-1}\)) and increasing concentrations of cold FH (0–100 \(\mu\)g mL\(^{-1}\)) for 1 h at 37 \(^\circ\)C. After washing with PBS, the radioactivity counts were measured in a gamma counter and the \(K_d\) value determined by a Scatchard equation and graph.

In order to establish the number of FH molecules bound per platelet, a state of equilibrium binding was achieved using increasing concentrations of radiolabeled FH (1, 10, 25, 50, 75 \(\mu\)g mL\(^{-1}\)) incubated for 1 h with 10\(^6\) mL\(^{-1}\) platelets. When equilibrium was attained the kinetics of binding was determined by measuring bound \(^{125}\)I-FH after 2, 10, 30 and 60 min.

**FH, constructs and mutant binding to tsp-1 detected by surface plasmon resonance**

Interactions of FH and tsp-1 were analyzed by the surface plasmon resonance technique using a Biacore 3000 instrument (Biacore AB, Uppsala, Sweden) as described [4,32]. Tsp-1 was coupled via a standard amine-coupling procedure to the flowcell of a sensor chip (carboxylated dextran chip CM5; Biacore) until an appropriate level of coupling for the binding experiments (> 4000 resonance units) was reached. A control flowcell was prepared without injecting protein. Native FH and recombinant construct SCRs 1–7, 8–11, 8–20 or 15–20 as well as SCR 15–20mut were dialyzed against the running buffer (PBS, pH 7.4, 7.5 mM NaCl). Each ligand (1 \(\mu\)l) was injected separately into the flowcell coupled with tsp-1 and into the control flowcell (without tsp-1). Each analysis was done at least twice using independently prepared sensor chips. For kinetic analysis of the interaction of FH with tsp-1, a concentration series of FH (1–320 nm) was run at a flow rate of 30 \(\mu\)l min\(^{-1}\) in three independent experiments on a chip with a lower surface density of tsp-1 (< 1000 resonance units) as described earlier [4]. For the heparin inhibition series, increasing concentrations of heparin (3–300 \(\mu\)g mL\(^{-1}\), low molecular weight; Sigma) were added to the analyte, SCR 15–20 (50 \(\mu\)g mL\(^{-1}\)), directly before the injection.

**Statistics**

Differences between platelets incubated with or without FH, with respect to binding, were assessed by the Mann–Whitney U-test. A \(P\)-value of \(\leq 0.05\) was considered significant. Statistical analyses were performed using SPSS version 11 (SPSS, Chicago, IL, USA).

**Results**

**FH binds to washed platelets**

FH bound to non-activated platelets and to platelets activated with either thrombin or ADP. Thrombin activation increased FH (10 \(\mu\)g mL\(^{-1}\)) binding by 22% (from 9 to 11% binding to the platelet population, median of three flow cytometry experiments) in comparison with non-activated platelets, and was also documented using radiolabeled FH (Fig. 1A).
number of radiolabeled FH molecules bound to each thrombin-activated platelet was $3.8 \times 10^5$, whereas the number of molecules bound to each resting platelet was $2.7 \times 10^5$. ADP activation increased FH (10 $\mu$g mL$^{-1}$) binding by 89% (from 9 to 17%, median of four flow cytometry experiments). Results pertaining to thrombin-activated platelets are shown. Binding was dose dependent as shown in Fig. 1B. A final concentration of 100 $\mu$g mL$^{-1}$ FH was incubated with platelets at 1 $\times$ 10$^7$ mL$^{-1}$ in an attempt to correspond to the ratio of FH to platelets in the human circulation (FH 500 $\mu$g mL$^{-1}$; platelets 1.4–4 $\times$ 10$^8$ mL$^{-1}$). At this concentration a median binding of 24% (polyclonal antibody) and 18% (monoclonal antibody) was found (Fig. 1B). FH binding as detected by fluorescence intensity using polyclonal and monoclonal

---

**Fig. 1.** Factor H (FH) binding to platelets. (A) A dose-dependent increase in binding of radiolabeled FH to thrombin-activated platelets (▲) vs. non-activated (▲). The abscissa shows the total amount of FH incubated with platelets and the ordinate shows the amount of FH that bound. In these experiments increasing concentrations of radiolabeled FH (1, 10, 25, 50, 75 $\mu$g mL$^{-1}$) were incubated with 10$^6$ mL$^{-1}$ platelets corresponding to the concentration conditions used in flow cytometry experiments which were 10-fold higher for both FH and platelets. Data were corrected for volume and are presented as amounts. (B) Thrombin-activated washed platelets incubated with or without FH. Dose-related binding detected by flow cytometry is shown. Statistical significance of platelets incubated with or without FH is given above each category. The number of experiments is given in parentheses below each category. The thin dark line in each box represents the median. The upper and lower limits of the box plot represent the interquartile range; the lower and upper limits represent the range. (C) One experiment showing FH 100 $\mu$g mL$^{-1}$ binding to 23.4% of platelets detected by the polyclonal antibody (thick line) after subtraction of the control antibody (thin line). (D) One experiment showing FH 100 $\mu$g mL$^{-1}$ binding to 28.9% of platelets detected by the monoclonal antibody (thick line) after subtraction of the control antibody (thin line). (E) Saturability was obtained at a FH concentration of approximately 500 $\mu$g mL$^{-1}$ detected by flow cytometry using the monoclonal anti-FH antibody (median of four experiments). The ordinate shows the percent of binding to the platelet population. (F) Kinetics of FH binding to platelets showing that maximal binding was achieved after 10 min incubation. The ordinate depicts the number of FH molecules bound per platelet.
antibodies is shown in Fig. 1C and D, respectively. Alexa555-labeled FH bound to 19.5% of platelets.

Saturability of FH binding to platelets (1 × 10^7 mL^{-1}) was obtained at a FH concentration of approximately 500 μg mL^{-1} (Fig. 1E). Maximal binding was noted after 10 min incubation (Fig. 1F).

The K_d of FH binding to platelets, tested by combining radiolabeled FH with cold FH and analyzed by a Scatchard plot, was 2.39 μM (data not shown).

Inhibition experiments using a F(ab')_2 fragment (goat antihuman FH) reduced binding by a mean of 42% (from 9.7 to 5.6%, two experiments).

**Mechanism by which FH binds to platelets**

In order to identify the mechanisms by which FH binds to platelets we localized the binding domain(s) within FH and tried to identify the receptor(s) on platelets that mediate binding.

**FH binds to platelets mainly via the C-terminus domain**

Recombinant constructs representing SCR 1–7, SCR 8–20 and SCR 15–20 of FH bound to platelets in a dose-related manner and all constructs that contained the C-terminus of FH (SCR 8–20 and SCR 15–20) showed strong binding (Table 1).

**Involvement of heparin-binding sites in FH binding to platelets**

Preincubation of FH with heparin reduced binding of FH to platelets by 36% (median of percentage reduction, from 32 to 18% binding, eight experiments). Preincubation of SCR 1–7, 8–20 and 15–20 with heparin reduced binding by 14, 23 and 22%, respectively. Preincubation of platelets with heparin before addition of FH had no effect on FH binding, indicating that the heparin-binding sites on FH and not on platelets are essential for this interaction. These results were further confirmed by incubating platelets with SCR 8–11, a construct lacking heparin-binding sites [33]. As shown in Table 1, binding of this construct was clearly reduced and no dose-response was demonstrated. Furthermore, preincubation with heparin did not reduce binding of this construct.

**Platelet GPIIb/IIIa receptor mediates FH binding**

The platelet GPIIb/IIIa receptor is essential for platelet interactions with fibrinogen, von Willebrand factor and other known platelet-activating peptides [34]. We therefore investigated if this receptor was involved in FH binding to platelets. This was achieved by blocking the receptor using an anti-GPIIb/IIIa antibody (Reopro®) and by competitive inhibition with fibrinogen.

Preincubation of platelets with Reopro® 100 μg mL^{-1} reduced binding of FH 100 μg mL^{-1} to platelets by 34% (median of percentage reduction) from 32 to 21% binding (seven experiments) (P < 0.02). Preincubation of platelets with Reopro® reduced binding of FH 10 μg mL^{-1} to platelets by 45% (median) from 19 to 11% binding (six experiments) (P < 0.03). As a control for platelet receptors, FH was preincubated with anti-GPIb antibody, which did not reduce binding.

Similar experiments were carried out using FH constructs to determine binding via the GPIIb/IIIa receptor. Reopro® 100 μg mL^{-1} reduced binding of SCR 1–7 by 36% (from 21 to 14% binding, three experiments), of SCR 8–20 by 32% (from 24 to 17%, three experiments) and of SCR 15–20 by 23% (from 32 to 25%, six experiments).

Washed platelets (not thrombin-activated) were incubated with or without FH, after which fibrinogen was added. Fibrinogen binding was detected on platelets not exposed to FH at a median of 44% (four experiments). When FH 10 μg mL^{-1} was present binding of fibrinogen was reduced to a median of 39% (11% reduction, four experiments). When FH 100 μg mL^{-1} was present binding of fibrinogen was reduced to a median of 35% (21% reduction, four experiments). These results indicate that the presence of the higher concentration of FH partially inhibited fibrinogen binding to the GPIIb/IIIa receptor and together with the above-mentioned Reopro® experiments suggest that GPIIb/IIIa is, to a certain extent, involved in FH binding to platelets via both the C- and N-termini.

A combination of Reopro® and heparin reduced FH binding to platelets from 32 to 13% (58% reduction, three experiments).

**FH binds to tsp-1 mainly via its C-terminus**

Since FH is secreted from platelets together with tsp-1, and FH binding to platelets was not totally abrogated by the
anti-GPIIb/IIIa antibody, we studied interactions between FH and tsp-1 and their importance for FH binding to platelets. We used the surface plasmon resonance technique to show binding of FH to immobilized tsp-1 and to determine the binding affinity and kinetics (Fig. 2A). The $K_d$ value for binding of FH to tsp-1 was 49 (± 4.4) nM at 25 °C. We localized the regions involved in binding using recombinant deletion constructs SCRs 1–7, 8–11, 8–20 and 15–20 (Fig. 2B). SCR 8–20 and SCR 15–20 bound to tsp-1. In contrast, construct SCR 1–7, containing the N-terminus, and SCR 8–11, did not bind to tsp-1.

The effect of heparin on the interaction between SCR 15–20 and tsp-1 was studied. The addition of heparin inhibited the interaction of SCR 15–20 with tsp-1 dose-dependently (Fig. 2C). This indicates that binding of SCR 15–20 to tsp-1 occurs at the heparin-binding site (SCR 20).

The above-mentioned experiments indicated that FH and tsp-1 interact with each other. We therefore investigated if these proteins are expressed on the surface of thrombin-activated platelets. Thrombin activation increased expression of tsp-1 4-fold (from 4 to 18% binding of the anti-tsp-1 antibody) and of FH by 0.5-fold (from 4 to 6% binding of the anti-FH antibody). This result suggests that FH may bind to activated platelets via surface expression of tsp-1.

Preincubation of platelets with anti-tsp-1 before addition of FH reduced FH binding by 36% (from 14 to 9%). Combination of tsp-1 with FH increased FH binding to platelets by 28% (median of percentage increase). This increase of FH binding was totally inhibited by preincubation of tsp-1 with anti-tsp-1. An attempt was made to inhibit FH binding by preincubation of FH with anti-tsp-1 and Reopro®, but these experiments could not be interpreted due to very high background fluorescence.

**Lack of C3 on washed platelets**

No C3 was identified on the surface of washed platelets. This indicates that FH does not bind to washed platelets via C3. When C3 was added to washed platelets (as the positive control) the anti-C3c antibody bound to 36% of the population (three experiments, data not shown).

---

**Fig. 2.** Binding of factor H (FH), FH constructs and mutant to thrombospondin-1 (tsp-1) detected by surface plasmon resonance. (A) Strong binding of FH to tsp-1 is shown. The inserted figure shows equilibrium binding of FH to tsp-1 expressed in resonance units at increasing concentrations of the analyte (FH concentrations from 1 to 320 nM). The controls (binding to a flowcell without immobilized protein) were subtracted from the binding curves. (B) FH constructs SCR 8–20 and SCR 15–20 bound to tsp-1 whereas SCR 8–11 and SCR 1–7 did not bind. (C) Heparin inhibited binding of SCR 15–20 to tsp-1 in a dose-dependent manner. (D) SCR 15–20mut exhibited weaker binding to tsp-1 than SCR 15–20.
Mutant FH binding to platelets and tsp-1

SCR 15–20mut bound to platelets significantly less than SCR 15–20 (P < 0.0001, Table 1). Binding was not inhibited by heparin but was reduced by Reopro® 100 µg mL⁻¹ by 50% (from 16 to 8%, six experiments) and by Reopro® 200 µg mL⁻¹ by 71% (from 16 to 5%, six experiments). Furthermore, SCR 15–20mut exhibited considerably lower binding to tsp-1 than SCR 15–20 as studied by surface plasmon resonance (Fig. 2D).

Discussion

A novel property of FH is presented in this study that shows binding of FH to washed platelets. FH mutated at the C-terminus exhibited significantly lower binding. This interaction occurred in the absence of complement and other plasma factors. FH mutations have been identified in a subset of patients with atypical HUS [7–12], a condition in which platelets are activated and consumed, leading to thrombocytopenia [13]. In some of these patients the alternative complement pathway is activated [35]. Although this study did not address the mechanisms by which platelets are activated in HUS, we have shown that, in a plasma-free environment, FH can interact with platelets and that mutated FH displays lesser binding.

FH binding to platelets is multivalent and may engage more than one site of the FH protein as well as various binding sites and different proteins on the platelet surface (Fig. 3). Binding seems to involve mainly the C-terminus of FH. The C-terminus contains C3b and heparin-binding sites. Recent studies provide evidence that this region is involved in binding to cell surfaces containing glycosaminoglycans such as sialic acids [3,4] and enables FH to differentiate between activating (foreign) and non-activating (host) surfaces [36]. FH binds to platelets directly via the GPIIb/IIIa receptor, which is exposed after platelet activation, or indirectly via tsp-1, which is expressed on the surface of activated platelets. Thus FH may bind via more specific mechanisms such as receptor-mediated binding, which may be inhibited by antibodies and competitive inhibition with fibrinogen, as well as less-specific mechanisms involving the heparin-binding sites of FH and glycosaminoglycans on cells. The complexity of FH binding and ligand specificity were previously documented for binding to C3b on erythrocytes [37,38].

Binding of FH to platelets involves the heparin-binding sites. The heparin-binding site at the C-terminus appears to be more accessible than the other two heparin-binding sites since heparin binding of the full protein can be inhibited by an antibody directed to the C-terminus [39]. This may explain why the N-terminus construct (SCR 1–7) binds to a lesser degree than the C-terminus construct (SCR 15–20) though both have one heparin-binding site. The SCR 8–11 construct, which lacks a heparin-binding site, has a binding site for C-reactive protein and binds to microbial ligands such as the pneumococcal Hic protein [33,40]. This construct bound platelets weakly and no binding to tsp-1 was detected. This further indicates that the heparin-binding sites are involved in binding of FH to platelets. In addition, our results suggest that binding of FH to GPIIb/IIIa occurs both at the C- and N-termini, whereas binding via tsp-1 occurs mostly via the C-terminus.

FH mutations in HUS patients have been mostly identified at the C-terminus of the protein. Using purified mutant FH from a HUS patient and a recombinant SCR 20-mutated construct, a recent study showed reduced binding to endothelial cells in comparison with the wild-type protein, suggesting that the mutated protein may not be capable of protecting the endothelial cell layer [17]. Mutated FH was capable of binding...
Factor H binds to washed human platelets

Current theories regarding the pathogenesis of HUS have focused on endothelial cell damage, with exposure of the subendothelium leading to deposition and consumption of platelets. We show that FH binds to platelets and suggest that this interaction may regulate complement activation on the platelet membrane. Reduced binding of mutated FH to platelets may promote uninhibited complement activation. Further studies are ongoing to address the interactions of FH with platelets in the presence of complement.

Acknowledgements

Presented in part at the XIX Complement Workshop, Palermo Sicily, 22–26 September 2002. This study was supported by grants from The Swedish Research Council (06X-14008), Knut and Alice Wallenberg Foundation, Swedish Renal Foundation, Åke Wiberg Foundation, Anna-Lisa and Sven-Eric Lundgren Foundation for Medical Research, Ronald McDonald Pediatric Fund, Greta and Johan Kock Foundation, Swedish Society of Medicine, Crafoord Foundation, Inga and John Hains Foundation, The Blood and Defence Network at Lund University, Royal Physiographic Society in Lund, Alfred Österlund Foundation, Crown Princess Lovisa’s Society for Child Care, Thelma Zoegas Foundation, The Swedish Society of Nephrology, Skånska Provinsiallogens Welfare Fund and the Lund University Hospital Funds (all to D.K.). The Sven Jerring Foundation (to F.V.-S. and D.K.). The Deutsche Forschungsgemeinschaft and Foundation for Children with Atypical HUS (to P.F.Z.). King Gustaf V’s 80th Birthday Fund (to A.G.S.).

References

4. Hell-wage J, Jokiranta TS, Friese MA, Wolk TU, Kampen E, Zipfel PF, Meri S. Complement C3b/C3d and cell surface polyanions are recognized by overlapping binding sites on the most carboxy-terminal domain of complement factor H. J Immunol 2002; 169: 6935–44.


